Trial Profile
A study investigating if everolimus immunosuppression reduces cytomegalovirus infection in renal transplant recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 07 Oct 2016 New trial record